Avelas Biosciences is a clinical-stage drug-device company focused on developing and commercializing pegloprastide (also known as AVB-620) with the goal of revolutionizing cancer surgery with real-time margin detection. In a prospective trial in women with early-stage breast cancer undergoing a lumpectomy, intraoperative imaging of pegloprastide detected up to 75% of the positive margins that resulted from standard-of-care techniques. Beyond breast cancer, pegloprastide has the potential to significantly improve outcomes in a variety of other cancer surgeries.
Oct 18, 2021
Avelas Makes Senior Appointments and Provides Update on Pegloprastide Phase III Clinical ProgramRead more
Apr 29, 2021
Avelas Biosciences Presents Phase 2, Period 2 Data in Virtual Poster Session at the 22nd Annual Meeting of The American Society of Breast SurgeonsRead more
Dec 14, 2020
Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer SurgeryRead more